UH's Cristina Rivera Garza is a 2020 MacArthur Fellowship winner. Photo courtesy of John D. & Catherine T. MacArthur Foundation

A prolific fiction writer and award-winning University of Houston academic has just received a major accolade. Distinguished professor Cristina Rivera Garza has been awarded a 2020 MacArthur Fellowship — dubbed more casually as a "genius" grant of a hefty $625,000 — the university announced.

The grant is a no-strings-attached gift "to extraordinarily talented and creative individuals as an investment in their potential," according to the John D. and Catherine T. MacArthur Foundation, which awards the grants each year. Rivera Garza is one of just 21 nationwide individuals to receive the fellowship grant.

Rivera Garza is founder and director of the UH doctoral program in Hispanic Studies with a concentration in creative writing in Spanish.

"This is an incredible — and quite unexpected — honor. I am suddenly short of words," said Rivera Garza in a statement. Amusingly, Rivera Garza told Andrew Dansby of the Houston Chronicle that she didn't take the MacArthur call at first Tuesday morning because she didn't recognize the number. She received an email asking for information about another candidate. "So I finally answered, and they delivered the news. It was quite a shock," she said.

She joins Rick Lowe, a UH professor of art who earned the fellowship in 2014, as the two MacArthur Fellows on faculty at UH. MacArthur Fellowships are among the most prestigious and generous awards given to those who have demonstrated extraordinary talent and dedication in academia, writing, music, film, and other creative fields, UH notes.

The majority of Rivera Garza's creative works are in Spanish but were written in the United States, where she has lived for more than 30 years. She earned her doctorate in Latin American history from the University of Houston in 1995 and was awarded an honorary degree from UH in 2012, according to UH. Rivera Garza joined the University of Houston faculty in 2016 and founded UH's Spanish-language creative writing concentration in 2017. She leads the program as its director.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.